Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 27;157:103189. doi: 10.1016/j.critrevonc.2020.103189

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — Schematic representation of the responses to the following survey’s questions: A Has the indication to adjuvant treatment been modified for surgically resected NSCLC patients? B Has the indication to concurrent chemo-radiotherapy been modified for NSCLC patients with unresectable locally advanced disease?. C Has the indication to first-line chemotherapy been modified for patients with metastatic NSCLC?. D Has the indication to first-line chemo-immunotherapy been modified for patients with metastatic NSCLC?. E Has the indication to first-line single agent immunotherapy been modified for patients with metastatic NSCLC?. F Has the indication to first-line targeted therapies been modified for patients with metastatic NSCLC? G Has treatment indication to first line chemotherapy or immunotherapy been modified in elderly patients (over 75 years) with non-oncogene addicted metastatic NSCLC?. H Has treatment indication to manteinance therapy benn modifed for patients with metastatic NSCLC candidate to start/continue maintenance chemotherapy (pemetrexed). I Has treatment indication for metastatic NSCLC patients undergoing first line immunotherapy been modified?. L Has treatment indication to second line chemotherapy been modified fro metastatic NSCLC patients?. M Has treatment indication to second line immunotherapy been modified for metastatic NSCLC patients?. N Has the indication to interrupt active treatment and start best supportive care been modified in metastatic NSCLC patients?. O Has follow-up management for NSCLC patients been modified?. P Has NSCLC patients’ accrual in ongoing clinical trials been modified?.

Fig. 2 — Schematic representation of the responses to the following survey’s questions: A Has the indication to adjuvant treatment been modified for surgically resected NSCLC patients? B Has the indication to concurrent chemo-radiotherapy been modified for NSCLC patients with unresectable locally advanced disease?. C Has the indication to first-line chemotherapy been modified for patients with metastatic NSCLC?. D Has the indication to first-line chemo-immunotherapy been modified for patients with metastatic NSCLC?. E Has the indication to first-line single agent immunotherapy been modified for patients with metastatic NSCLC?. F Has the indication to first-line targeted therapies been modified for patients with metastatic NSCLC? G Has treatment indication to first line chemotherapy or immunotherapy been modified in elderly patients (over 75 years) with non-oncogene addicted metastatic NSCLC?. H Has treatment indication to manteinance therapy benn modifed for patients with metastatic NSCLC candidate to start/continue maintenance chemotherapy (pemetrexed). I Has treatment indication for metastatic NSCLC patients undergoing first line immunotherapy been modified?. L Has treatment indication to second line chemotherapy been modified fro metastatic NSCLC patients?. M Has treatment indication to second line immunotherapy been modified for metastatic NSCLC patients?. N Has the indication to interrupt active treatment and start best supportive care been modified in metastatic NSCLC patients?. O Has follow-up management for NSCLC patients been modified?. P Has NSCLC patients’ accrual in ongoing clinical trials been modified?.